Open AccessTGF-β-Induced TMEPAI Promotes Epithelial–Mesenchymal Transition in Doxorubicin-Treated Triple-Negative Breast Cancer Cells via SMAD3 and PI3K/AKT Pathway Alteration
Author(s) -
Bantari W. K. Wardhani,
Melva Louisa,
Yuji Watanabe,
Rianto Setiabudy,
Mitsuyasu Kato
Publication year - 2021
Publication title -
breast cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.19
H-Index - 27
ISSN - 1179-1314
DOI - 10.2147/bctt.s325429
Subject(s) - doxorubicin , cancer research , triple negative breast cancer , epithelial–mesenchymal transition , protein kinase b , pi3k/akt/mtor pathway , cancer cell , cancer , breast cancer , pten , medicine , apoptosis , chemistry , metastasis , chemotherapy , biochemistry
Epithelial-mesenchymal transition (EMT) and overexpression of drug efflux transporters have been reported to cause doxorubicin resistance. Our previous study indicated that TMEPAI (transmembrane prostate androgen-induced protein) attenuated doxorubicin sensitivity in triple-negative breast cancer cells. However, how TMEPAI contributes to doxorubicin resistance in TNBC remains unclear. Thus, the present study aimed to elucidate the mechanism of TMEPAI in doxorubicin resistance in triple-negative breast cancer cells.